Clinical Efficacy Analysis of Rivaroxaban Dosage in Patients with Ventricular Thrombus

This study aimed to investigate the efficacy of different dosages of rivaroxaban in the treatment of ventricular thrombus. From February 2023 to February 2025, 86 patients from the Department of Cardiology of our hospital were selected and divided into two groups based on the dosage of rivaroxaban: the low-dose group (10 mg/d) and the standard-dose group (20 mg/d). Post-treatment outcomes, including thrombus area, dissolution rate, bleeding events, cardiac function improvement, and changes in D-dimer levels, were observed. Results indicated that after treatment, the standard-dose group showed superior outcomes in thrombus area reduction (P < 0.05), with complete thrombus dissolution and total effective rates of 67.44% and 88.37%, respectively, compared to 44.19% and 74.42% in the low-dose group (P < 0.05). However, the incidence of bleeding events was lower in the low-dose group (P < 0.05). Additionally, after 3 months of treatment, the standard-dose group exhibited a more pronounced decrease in D-dimer levels (P < 0.05). In conclusion, rivaroxaban at a standard dosage of 20 mg/d is more effective than a low dosage of 10 mg/d in reducing thrombus area and D-dimer levels in patients with ventricular thrombus, though it carries an increased risk of mild bleeding. Clinicians should tailor the dosage based on individual patient conditions to optimize therapeutic efficacy and safety.